ArticleOncogene2008
Inhibition of transcriptional activation and cell proliferation activities of adenovirus E1A by the unique N-terminal domain of CtBP2.
Article in Oncogene, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Review
- NSM00158 Specifically Disrupts the CtBP2-p300 Interaction to Reverse CtBP2-Mediated Transrepression and Prevent the Occurrence of Nonunion.Molecules and cells · 2020Article
- Sumoylation regulates interaction of FOG1 with C-terminal-binding protein (CTBP).The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The 243-residue E1A protein of adenovirus induces cellular proliferation, at least partly by regulating the transcription of cellular genes. This E1A function requires E1A N-terminal region and conserved regions 1 and 2 (CR1 and CR2), which interact with histone acetyl transferases, p400 chromatin-modifying complex and the Rb family proteins. A PLDLS motif at the E1A C-terminal (CR4) region, interacts with the C-terminal binding proteins (CtBP1 and CtBP2), and antagonizes some E1A functions. In this report, we discovered that the transcriptional activation function of E1A was specifically repressed by a short N-terminal domain unique to CtBP2. The CtBP2-mediated repression of E1A transcriptional activation activity is independent of histone deacetylases, which can be recruited by CtBP1/2 proteins to inhibit transcription. Fusion of the CtBP2 N-terminal 20 residues to the E1A C-terminal region rendered E1A to be inactive in transcriptional activation without interfering with E1A's ability to interact with major cofactors such as pRb, p400 and p300. Substitution of the N-terminal domain of CtBP1 for the CtBP2 domain in E1A-CtBP2 fusion partially restored the transactivation activity of E1A. In a cell-proliferation model utilizing primary baby rat kidney cells and retrovirally expressed E1A, the ability of E1A to induce cellular proliferation was strongly inhibited when the CtBP2 N-terminal region was fused to E1A. These results are consistent with a hypothesis that CtBP2 may inhibit E1A induced cell proliferation by antagonizing the transcriptional activation function controlled by the N-terminal region of E1A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.